Lantern Pharma (LTRN), Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Lantern Pharma (LTRN), Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform

Lantern Pharma (LTRN) Tops Q1 EPS by 3c

May 3, 2021 4:58 PM EDT

Lantern Pharma (NASDAQ: LTRN) reported Q1 EPS of ($0.24), $0.03 better than the analyst estimate of ($0.27).

"We are very pleased with our continued rapid progress in expanding and advancing our pipeline of targeted cancer drug candidates and are on pace to launch the Phase 2 trial of LP-300 in non-small cell lung cancer among non-smokers in the third quarter of this year," stated Panna Sharma, President and... More